These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37944867)

  • 1. Discovery of 3-oxo-1,2,3,4-tetrahydropyrido[1,2-a]pyrazin derivatives as SARS-CoV-2 main protease inhibitors through virtual screening and biological evaluation.
    Dou X; Sun Q; Liu Y; Lu Y; Zhang C; Xu G; Xu Y; Huo T; Zhao X; Su L; Xing Y; Lai L; Jiao N
    Bioorg Med Chem Lett; 2024 Jan; 97():129547. PubMed ID: 37944867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of 2-(furan-2-ylmethylene)hydrazine-1-carbothioamide derivatives as novel inhibitors of SARS-CoV-2 main protease.
    Dou X; Sun Q; Xu G; Liu Y; Zhang C; Wang B; Lu Y; Guo Z; Su L; Huo T; Zhao X; Wang C; Yu Z; Song S; Zhang L; Liu Z; Lai L; Jiao N
    Eur J Med Chem; 2022 Aug; 238():114508. PubMed ID: 35688005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-based discovery of thiosemicarbazones as SARS-CoV-2 main protease inhibitors.
    Maltarollo VG; da Silva EB; Kronenberger T; Sena Andrade MM; de Lima Marques GV; Cândido Oliveira NJ; Santos LH; Oliveira Rezende Júnior C; Cassiano Martinho AC; Skinner D; Fajtová P; M Fernandes TH; Silveira Dos Santos ED; Rodrigues Gazolla PA; Martins de Souza AP; da Silva ML; Dos Santos FS; Lavorato SN; Oliveira Bretas AC; Carvalho DT; Franco LL; Luedtke S; Giardini MA; Poso A; Dias LC; Podust LM; Alves RJ; McKerrow J; Andrade SF; Teixeira RR; Siqueira-Neto JL; O'Donoghue A; de Oliveira RB; Ferreira RS
    Future Med Chem; 2023 Jun; 15(11):959-985. PubMed ID: 37435731
    [No Abstract]   [Full Text] [Related]  

  • 4. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
    Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multi-stage virtual screening of FDA-approved drugs reveals potential inhibitors of SARS-CoV-2 main protease.
    Mandour YM; Zlotos DP; Alaraby Salem M
    J Biomol Struct Dyn; 2022 Mar; 40(5):2327-2338. PubMed ID: 33094680
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of potential inhibitors based on isatin derivatives against SARS-CoV-2 main protease (m
    Badavath VN; Kumar A; Samanta PK; Maji S; Das A; Blum G; Jha A; Sen A
    J Biomol Struct Dyn; 2022 Apr; 40(7):3110-3128. PubMed ID: 33200681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 3-phenyl-1,2,4-oxadiazole derivatives as a new class of SARS-CoV-2 main protease inhibitors.
    Guo N; Huang C; Qiao J; Li Y; Wang Y; Xia A; Zhang G; Fang Z; You J; Li L
    Bioorg Med Chem Lett; 2023 Apr; 86():129238. PubMed ID: 36924946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.
    Fakhar Z; Khan S; AlOmar SY; Alkhuriji A; Ahmad A
    Sci Rep; 2021 Jan; 11(1):234. PubMed ID: 33420186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
    Ghosh A; Chakraborty M; Chandra A; Alam MP
    J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and structure-activity relationship studies of novel α-ketoamide derivatives targeting the SARS-CoV-2 main protease.
    Huang C; Zeng R; Qiao J; Quan B; Luo R; Huang Q; Guo N; Li Y; Long X; Ma R; Xia A; Fang Z; Wang Y; Li Y; Zheng Y; Li L; Lei J; Yang S
    Eur J Med Chem; 2023 Nov; 259():115657. PubMed ID: 37517202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-Based Discovery of Novel Nonpeptide Inhibitors Targeting SARS-CoV-2 M
    Yang J; Lin X; Xing N; Zhang Z; Zhang H; Wu H; Xue W
    J Chem Inf Model; 2021 Aug; 61(8):3917-3926. PubMed ID: 34279924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of α-Ketoamide inhibitors of SARS-CoV-2 main protease derived from quaternized P1 groups.
    Huang Q; Quan B; Chen Y; Zhao X; Zhou Y; Huang C; Qiao J; Wang Y; Li Y; Yang S; Lei J; Li L
    Bioorg Chem; 2024 Feb; 143():107001. PubMed ID: 38101266
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of high-affinity inhibitors of SARS-CoV-2 main protease: Towards the development of effective COVID-19 therapy.
    Mohammad T; Shamsi A; Anwar S; Umair M; Hussain A; Rehman MT; AlAjmi MF; Islam A; Hassan MI
    Virus Res; 2020 Oct; 288():198102. PubMed ID: 32717346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of benzodiazepine derivatives as a new class of covalent inhibitors of SARS-CoV-2 main protease.
    Wang F; Zeng R; Qiao J; Xia A; Li Y; Li F; Wu Y; Liu Y; Zhao X; Lei J; Yang S
    Bioorg Med Chem Lett; 2023 Aug; 92():129407. PubMed ID: 37437852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
    Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
    Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
    Rocha REO; Chaves EJF; Fischer PHC; Costa LSC; Grillo IB; da Cruz LEG; Guedes FC; da Silveira CH; Scotti MT; Camargo AD; Machado KS; Werhli AV; Ferreira RS; Rocha GB; de Lima LHF
    J Biomol Struct Dyn; 2022; 40(19):9214-9234. PubMed ID: 33970798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.